813 results on '"Schouten, Harry C."'
Search Results
102. Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkinʼs Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40
103. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:: A randomised phase II trial from HOVON, the Dutch–Belgian Haemato-Oncology Working Group for adults
104. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients : Center for International Blood and Marrow Transplant Research Report
105. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
106. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
107. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24) : a randomised, open-label, phase 3 intergroup study
108. Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment
109. Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature
110. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
111. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
112. High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial
113. Partially T-Cell–Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM
114. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
115. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
116. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
117. Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation
118. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.
119. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation
120. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
121. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
122. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
123. Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
124. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission
125. Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party
126. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
127. The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies
128. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor–mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
129. Quality of life after stem cell transplantation: a patient, partner and physician perspective
130. Cell turnover parameters in small and large cell varieties of primary intestinal non-Hodgkin's lymphoma
131. Large-cell anaplastic non-Hodgkin's lymphoma originating in donor cells after allogenic bone marrow transplantation
132. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
133. Correspondence: Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation
134. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen
135. Improved survival after acute graft
136. In the Era of Chemoimmunotherapy, Relapse Post Autologous Stem Cell Transplantation for Follicular Lymphoma Is Associated with Prolonged Overall Survival. an Analysis By the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
137. Rituximab‐PECC induction followed by 90Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
138. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen
139. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
140. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
141. Impact of Donor Type in Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Conditioning: A Study From the Alwp of the Ebmt and Eurocord
142. No Benefit of Rituximab in Primary Central Nervous System Lymphoma Patients: Results of the Randomised Phase III HOVON 105 / ALLG NHL 24 Intergroup Study
143. Screening for platelet function disorders with Multiplate and platelet function analyzer
144. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission
145. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms : an analysis by the MPN QOL International Working Group
146. Therapeutic value of clofarabine in younger and middle aged (18 - 65 yrs) adults with newly diagnosed AML.
147. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.
148. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
149. Improved survival after acute graft-versus-host disease diagnosis in the modern era.
150. Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.